The CADTH pCODR Expert Review Committee Process Explained. Comment on Rayson et al. Access to Neoadjuvant Pertuzumab for HER2 Positive Breast Cancer in Canada: A Dilemma Increasingly Difficult to Explain. Curr. Oncol. 2022, 29, 9891–9895

Detalles Bibliográficos
Autores principales: Trudeau, Maureen, Fraser, Brent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217326/
https://www.ncbi.nlm.nih.gov/pubmed/37232838
http://dx.doi.org/10.3390/curroncol30050380

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10217326/
https://www.ncbi.nlm.nih.gov/pubmed/37232838
http://dx.doi.org/10.3390/curroncol30050380

Ejemplares similares